A Halliday

Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu).

SPONTANEOUS/IDIOPATHIC URTICARIA PATIENTS: RESULTS FROM THE FIRST INTERNATIONAL BURDEN OF ILLNESS STUDY (ASSURE-CSU) Balp MM1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Maurer M6, Koenders J7, Knulst AC8, Halliday A9, Alexopoulos ST9, Nakonechna A10, Grattan C11, Abuzakouk M12, Sweeney C13, Radder C13, Wolin D14, McBride D15, Hollis K13, Tian H16, Oude Elberink JNG17 1Novartis Pharma AG, Basel, Switzerland | 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada | 3Lynderm Research Inc., Toronto, ON, Canada | 41St Michael’s Hospital, University of Toronto, Toronto, ON, Canada | 5Novartis Pharma GmbH, Nuernberg, Germany | 6Charite Universitatsmedizin Berlin, Berlin, Germany | 7Novartis Pharma B.V., Arnhem, Netherlands | 8University Medical Center Utrecht, Utrecht, Netherlands, 9Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom | 10Royal Liverpool and Broadgreen University Hospitals NHS Trust, United Kingdom | 11Norfolk and Norwich University Hospital, Norwich, United Kingdom, 12Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, UAE | 13RTI Health Solutions, Research Triangle Park, NC, USA | 14RTI Health Solutions, Ann Arbor, MI, USA | 15RTI Health Solutions, Manchester, United Kingdom | 16Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA | 17University Medical Center Groningen, Groningen, Netherlands

Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (Csu).

Background Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society.

Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK

ObjectiveTo determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population).Perspective and SettingUK National Health Service (NHS).MethodsThe model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%.ResultsIn the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population.ConclusionsEven at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.

Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom:

Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into differential indirect cost savings is unknown.

First Real-World Study Assessing Health Utility Values For Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d

CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA USING THE EQ-5D McBride D1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Maurer M6, Koenders J7, Knulst AC8, Oude Elberink JNG9, Halliday A10, Alexopoulos ST10, Nakonechna A11, Abuzakouk M12, Sweeney C13, Radder C13, Wolin D14, Hollis K13, Tian H15, Balp MM16, Grattan C17 1RTI Health Solutions, Manchester, United Kingdom | 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada | 3Lynderm Research Inc., Toronto, ON, Canada | 41St Michaels Hospital, University of Toronto, Toronto, ON, Canada | 5Novartis Pharma GmbH, Nuernberg, Germany | 6Charite Universitätsmedizin Berlin, Berlin, Germany | 7Novartis Pharma B.V., Arnhem, Netherlands | 8University Medical Center Utrecht, Utrecht, Netherlands | 9University Medical Center Groningen, Groningen, Netherlands | 10Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom | 11Royal Liverpool and Broadgreen University Hospitals NHS Trust, United Kingdom | 12Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, UAE | 13RTI Health Solutions, Research Triangle Park, NC, USA | 14RTI Health Solutions, Ann Arbor, MI, USA | 15Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA | 16Novartis Pharma AG, Basel, Switzerland | 17Norfolk and Norwich University Hospital, Norwich, United Kingdom